Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TERNS PHARMACEUTICALS, INC.

(TERN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Terns Pharmaceuticals : Reports Positive Results in Study of Drug Candidate for Non-Alcoholic Steatohepatitis

06/14/2021 | 08:04am EDT


ę MT Newswires 2021
All news about TERNS PHARMACEUTICALS, INC.
08/04Certain Common Stock of Terns Pharmaceuticals, Inc. are subject to a Lock-Up ..
CI
08/04Certain Stock Options of Terns Pharmaceuticals, Inc. are subject to a Lock-Up..
CI
08/03TERNS PHARMACEUTICALS : to Present at Upcoming Investor Conferences
AQ
06/24TERNS PHARMACEUTICALS : Starts Patient Dosing in Phase 1b Trial of Liver Disease..
MT
06/24Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinic..
GL
06/24Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinic..
CI
06/21TERNS PHARMACEUTICALS, INC.(NASDAQGS : TERN) added to S&P Global BMI Index
CI
06/14TERNS PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (f..
AQ
06/14TERNS PHARMACEUTICALS : Reports Positive Top-line Results from Phase 2a LIFT Stu..
PU
06/14TERNS PHARMACEUTICALS : Reports Positive Results in Study of Drug Candidate for ..
MT
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -64,8 M - -
Net cash 2021 102 M - -
P/E ratio 2021 -2,32x
Yield 2021 -
Capitalization 205 M 205 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 30
Free-Float 98,9%
Chart TERNS PHARMACEUTICALS, INC.
Duration : Period :
Terns Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TERNS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 8,18 $
Average target price 30,50 $
Spread / Average Target 273%
EPS Revisions
Managers and Directors
Senthil Sundaram Chief Executive Officer & Director
Erin Quirk President & Chief Medical Officer
Mark J. Vignola Chief Financial Officer & Treasurer
David A. Fellows Chairman
Weidong Zhong Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
TERNS PHARMACEUTICALS, INC.0.00%205
MODERNA, INC.301.12%168 260
LONZA GROUP AG26.76%59 023
IQVIA HOLDINGS INC.39.45%47 876
CELLTRION, INC.-25.07%32 166
SEAGEN INC.-6.81%29 694